AI Engines For more Details: Perplexity Kagi Labs You
Radiosensitization in Cancer Treatment: Etanidazole is primarily used as a radiosensitizer in combination with radiation therapy for the treatment of certain types of cancer, particularly brain tumors such as glioblastoma multiforme (GBM). As a radiosensitizer, etanidazole enhances the effects of radiation therapy by increasing the sensitivity of tumor cells to radiation, thereby improving the efficacy of treatment.
Hypoxic Tumor Cells: One of the mechanisms of action of etanidazole is its ability to selectively target and sensitize hypoxic tumor cells to radiation therapy. Hypoxic (low-oxygen) tumor cells are often more resistant to radiation treatment, and etanidazole helps overcome this resistance by increasing the radiosensitivity of these cells.
Potential Side Effects: Like other medications, etanidazole may cause side effects, although these can vary depending on factors such as dosage, duration of treatment, and individual patient characteristics. Common side effects may include nausea, vomiting, diarrhea, headache, dizziness, and allergic reactions. In some cases, etanidazole may also cause neurotoxicity or peripheral neuropathy.
Research and Development: Etanidazole has also been investigated for its potential use in other medical conditions, such as ischemic stroke and neuroprotection, due to its ability to modulate cellular responses to hypoxia. However, further research is needed to determine its efficacy and safety in these areas.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1.8 | 0.3 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.8 | 0.5 |
| Allergies | 1.9 | 1.3 | 0.46 |
| Allergy to milk products | 1.2 | 0.9 | 0.33 |
| Alzheimer's disease | 2.3 | 3.7 | -0.61 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.6 | 1.17 |
| Ankylosing spondylitis | 1.6 | 0.9 | 0.78 |
| Anorexia Nervosa | 0.6 | 2.1 | -2.5 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 2.1 | 1.1 | 0.91 |
| Atherosclerosis | 1.6 | 0.6 | 1.67 |
| Atrial fibrillation | 1.9 | 1.3 | 0.46 |
| Autism | 4.2 | 4.3 | -0.02 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.1 | 1.1 | |
| Bipolar Disorder | 1.2 | 1.1 | 0.09 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.3 | 0.6 | -1 |
| Carcinoma | 2.1 | 0.6 | 2.5 |
| Celiac Disease | 2 | 0.6 | 2.33 |
| Cerebral Palsy | 0.6 | 1.1 | -0.83 |
| Chronic Fatigue Syndrome | 1.8 | 2.7 | -0.5 |
| Chronic Kidney Disease | 1.2 | 1.4 | -0.17 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.4 | -0.08 |
| Chronic Urticaria (Hives) | 1.2 | 0.6 | 1 |
| Coagulation / Micro clot triggering bacteria | 1.2 | 1.1 | 0.09 |
| Cognitive Function | 0.9 | 0.8 | 0.13 |
| Colorectal Cancer | 4.7 | 1.7 | 1.76 |
| Constipation | 1.8 | 0.5 | 2.6 |
| Coronary artery disease | 1.7 | 1.8 | -0.06 |
| COVID-19 | 2.7 | 3.5 | -0.3 |
| Crohn's Disease | 4.3 | 2.4 | 0.79 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.9 | 0.8 | 0.13 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.9 | 1.4 | 0.36 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 4.8 | 4.2 | 0.14 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.2 | 0.7 | 0.71 |
| Endometriosis | 1.7 | 1.4 | 0.21 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.2 | 0.3 | 6.33 |
| erectile dysfunction | 1.2 | 1.2 | |
| Fibromyalgia | 0.5 | 1.2 | -1.4 |
| Functional constipation / chronic idiopathic constipation | 3.2 | 2.4 | 0.33 |
| gallstone disease (gsd) | 1.6 | 0.8 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 0.3 | 4.33 |
| Generalized anxiety disorder | 2 | 0.9 | 1.22 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1 | 0.3 | 2.33 |
| Graves' disease | 0.6 | 1.7 | -1.83 |
| Gulf War Syndrome | 0.6 | 0.4 | 0.5 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 2.2 | 0.6 | 2.67 |
| Heart Failure | 2.3 | 1.1 | 1.09 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.8 | 0.3 | 1.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 0.9 | 0.3 | 2 |
| hypertension (High Blood Pressure | 1.8 | 2.1 | -0.17 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 1.2 | 1.2 | |
| IgA nephropathy (IgAN) | 1.2 | 0.8 | 0.5 |
| Inflammatory Bowel Disease | 3.1 | 3.8 | -0.23 |
| Insomnia | 0.9 | 1.7 | -0.89 |
| Intelligence | 1 | 0.2 | 4 |
| Intracranial aneurysms | 0.9 | 0.3 | 2 |
| Irritable Bowel Syndrome | 3.4 | 2.4 | 0.42 |
| ischemic stroke | 1.2 | 1.7 | -0.42 |
| Liver Cirrhosis | 3.6 | 2.3 | 0.57 |
| Long COVID | 3 | 2.2 | 0.36 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.6 | 0.3 | 1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.6 | 1 |
| ME/CFS with IBS | 0.3 | 0.9 | -2 |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 3.3 | 3.1 | 0.06 |
| Mood Disorders | 3.9 | 4.1 | -0.05 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 2.3 | 2.6 | -0.13 |
| Multiple system atrophy (MSA) | 0.2 | 0.3 | -0.5 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 0.8 | -0.8 | |
| Neuropathy (all types) | 0.3 | 1.1 | -2.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.8 | 1.7 | 0.65 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.4 | 3.3 | 0.03 |
| obsessive-compulsive disorder | 2.8 | 1.7 | 0.65 |
| Osteoarthritis | 1.3 | 0.9 | 0.44 |
| Osteoporosis | 1.7 | 0.6 | 1.83 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 3.3 | 3.9 | -0.18 |
| Polycystic ovary syndrome | 3.9 | 1.7 | 1.29 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.3 | 0.7 | -1.33 |
| Primary sclerosing cholangitis | 1.1 | 0.6 | 0.83 |
| Psoriasis | 1.3 | 1.6 | -0.23 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 2.1 | 0.43 |
| Rosacea | 0.6 | 0.5 | 0.2 |
| Schizophrenia | 1.6 | 1.4 | 0.14 |
| scoliosis | 0.6 | 0.3 | 1 |
| Sjögren syndrome | 1.1 | 0.7 | 0.57 |
| Sleep Apnea | 0.9 | 1.4 | -0.56 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.9 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 1.4 | |
| Stress / posttraumatic stress disorder | 1.4 | 1.1 | 0.27 |
| Systemic Lupus Erythematosus | 2.2 | 0.8 | 1.75 |
| Tic Disorder | 1.2 | 0.2 | 5 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.8 | 2 | 0.4 |
| Type 2 Diabetes | 4.5 | 3.4 | 0.32 |
| Ulcerative colitis | 2.8 | 2.7 | 0.04 |
| Unhealthy Ageing | 2.8 | 1.1 | 1.55 |
| Vitiligo | 1.3 | 0.6 | 1.17 |
